Fagron Joins Low Dose Naltrexone Research Trust to Support Patient Care

In the realm of medical research, groundbreaking discoveries often emerge from the dedicated efforts of organizations and individuals committed to advancing the boundaries of knowledge. The Low Dose Naltrexone (LDN) Research Trust stands as a shining example of such an organization, tirelessly working to uncover the therapeutic potential of LDN for various medical conditions. Fagron, a 2023 LDN Research Trust Corporate Member, supports the mission of the LDN Research Trust and how these advancements contribute to the future of personalized medicine.  

The Low Dose Naltrexone Research Trust, established in 2004, is a non-profit organization dedicated to promoting research and education about Low Dose Naltrexone. As indicated by LDN Research Trust, LDN is most commonly being used for Chronic Fatigue Syndrome, multiple sclerosis, myalgia encephalopathy, autoimmune thyroid diseases, and various cancers. Many autoimmune diseases seem to respond to LDN¹.

Led by a team of medical and pharmacist advisors, the LDN Research Trust has been instrumental in fostering collaboration between researchers, clinicians, and patients interested in LDN. Through their efforts, they have been able to raise awareness, fund research studies, and compile a growing body of evidence supporting the potential benefits of LDN. Visit ldnresearchtrust.org/ for more information, resources, and patient testimonials.

Fagron joined the LDN Research Trust to increase opportunities for pharmaceutical discoveries that may lead to enhanced patient care.  

‍

“We are excited for the opportunity to support the LDN Research Trust, and the research it undertakes has the potential to help so many patients,” commented Gregory Lake, President of Fagron Brands and Essentials. “As the global leader in pharmaceutical compounding, Fagron is uniquely positioned to help pharmacists embrace new therapeutic options, like Low Dose Naltrexone, with high-quality products, robust educational resources, and technical experience. We want to support pharmacists and providers as they introduce new treatment options to help patients with their individual needs.”

‍

Fagron's membership in the LDN Research Trust highlights its commitment to fostering innovation across the industry. Combined with the Trust’s mission to explore LDN's effectiveness for various conditions, Fagron continues to create the future of personalizing medicine, and empower pharmacists and providers to optimize patient outcomes.  

Visit fagron.us or call our experienced team at (800) 423 6967 to learn more.  

‍